Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine-Tucson in 1988, and completed a residency in Obstetrics and Gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in Medical Genetics and Gynecologic Oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until 2010, was Associate Professor with Tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr. Monk was then appointed Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. In 2016, he became a member of Arizona Oncology and part of the US Oncology Network and continues to practice in Phoenix. Most recently, he has been appointed the US Oncology Medical Director of Gynecologic Oncology Research. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix and works at Arizona Oncology (US Oncology Network). Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy in recurrent cervical cancer in 2014 and advanced ovarian in 2018. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Finally, his other papers in the New England Journal of Medicine and Lancet Oncology have led to four FDA approvals of PARP inhibitors is ovarian cancer. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer and is on the Board of Directors for the GOG Foundation, Inc. and was the Cervical Cancer Sub-Committee Chair for NRG Oncology for 11 years. He currently chairs the Cervical Cancer Committee for the Gynecologic Cancer Intergroup (GCIG). Finally, he is Vice President and on the Board of Directors for the GOG Foundation and Co-directs the GOG Partners Research consortium as well as being the lead investigator (Director) of gynecologic cancers in the US Oncology Network (USON). Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists) and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncology, International Gynecologic Cancer Society and American Society of Clinical Oncology. He has authored more than 360 peer-reviewed articles along with more than 30 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.